| Literature DB >> 35209235 |
Dario Matulja1, Filip Vranješević1, Maria Kolympadi Markovic1, Sandra Kraljević Pavelić2, Dean Marković1.
Abstract
Since the middle of the last century, marine organisms have been identified as producers of chemically and biologically diverse secondary metabolites which have exerted various biological activities including anticancer, anti-inflammatory, antioxidant, antimicrobial, antifouling and others. This review primarily focuses on the marine phenolic compounds and their derivatives with potent anticancer activity, isolated and/or modified in the last decade. Reports on the elucidation of their structures as well as biosynthetic studies and total synthesis are also covered. Presented phenolic compounds inhibited cancer cells proliferation or migration, at sub-micromolar or nanomolar concentrations (lamellarins D (37), M (38), K (39), aspergiolide B (41), fradimycin B (62), makulavamine J (66), mayamycin (69), N-acetyl-N-demethylmayamycin (70) or norhierridin B (75)). In addition, they exhibited anticancer properties by a diverse biological mechanism including induction of apoptosis or inhibition of cell migration and invasive potential. Finally, phlorotannins 1-7 and bromophenols 12-29 represent the most researched phenolic compounds, of which the former are recognized as protective agents against UVB or gamma radiation-induced skin damages. Finally, phenolic metabolites were assorted into six main classes: phlorotannins, bromophenols, flavonoids, coumarins, terpenophenolics, quinones and hydroquinones. The derivatives that could not be attributed to any of the above-mentioned classes were grouped in a separate class named miscellaneous compounds.Entities:
Keywords: anticancer; marine natural products; phenolics
Mesh:
Substances:
Year: 2022 PMID: 35209235 PMCID: PMC8879422 DOI: 10.3390/molecules27041449
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.411
Scheme 1Main biosynthetic pathways for generation of phenolic compounds.
Figure 1Chemical structures of phlorotannins 1–7 with anticancer activities isolated from brown seaweeds.
Figure 2Chemical structures of bromophenols 8–29 with significant anticancer activities isolated from brown, red and green seaweeds.
Figure 3Chemical structures of flavonoids, penimethavone A (30), isolated from fungus Penicillium chrysogenum and flavonoid glycosides 31–34 isolated from the halophytes, Salicornia herbacea and Limonium tetragonum.
Figure 4Chemical structures of coumarins: alternariol (35) and its analogue 36 isolated from the mangrove endophytic fungus 2240. Lamellarins D (37), M (38) and K (39) are obtained from the marine molluscs of the genus Lamellaria. Aspergiolides A (40) and B (41) are extracted from the marine fungus, Aspergillus galucus.
Figure 5Chemical structures of meroditerpenes 42–47 isolated from brown algae (Stypopodium spp.). Sesquiterpenes 48–50 isolated from red algae (Laurencia spp.), 51 isolated from sponge, Didiscus flavus, and plastoquinones 52–55 isolated from brown algae Sargassum sp.
Figure 6Chemical structures of moromycin B (56), saquayamycins B (57) and B1 (58) isolated from the Streptomyces sp. OC1610.4 strain, buanmycin (59), isolated from the Streptomyces strain, SNR69, komodoquinone A (60), isolated from the Streptomyces sp. KS3 strain and fradimycin A (61), fradimycin B (62) and MK844-mF10 (63), isolated from the Streptomyces fradiae strain PTZ0025.
Figure 7Makaluvamines D (64), K (65), J (66), P (67) and F (68) isolated from the two sponge genera of Zyzzya and Latrunculi, mayamycin (69) and N-acetyl-N-demethylmayamycin (70) isolated from the Streptomyces sp. strains HB202 and 182SMLY, respectively; monacyclinone F (71) isolated from the Streptomyces sp. strain M7_15, galvaquinone B (72) and lupinacidin A (73) isolated from the Streptomyces spinoverrucosus and hierridin B (74) isolated from the Phormidium ectocarpi and Cyanobium sp. and its structural analogue, norhierrdin B (75).
Figure 8Diorcinol L (76) isolated from the fungus of the genus Didymellaceae and its derivative 77, sulochrin (78) obtained from the fungus Aspergillus falconensis, penicitrinine A (79) isolated from the Penicillium citrinum, psammaplin A (80) extracted from the marine sponge of the genus Pseudoceratina, and secalonic acids D (81) and F (82) obtained from Penicillium sp. and Aspergillus aculeatus.
Anticancer properties of marine-derived phenolic compounds obtained by different experimental systems (in vitro, in vivo or in silico).
| Compound | Class | Anticancer Properties Displayed by In Vitro, In Vivo or In Silico Experiments | Ref. |
|---|---|---|---|
| Phloroglucinol | Phlorotannin | Inhibition of migration and capillary-tube formation resulting in reduction of Lewis lung carcinoma in mouse model | [ |
| 50% of MDA-MB-231 cells’ migration at 50 µM by inhibiting epithelial-mesenchymal cell transition via downregulation of SLUG protein | [ | ||
| Apoptosis of the HT-29 cells through insulin-like growth factor 1 receptor (IGF-1R) and inhibition of downstream proteins | [ | ||
| Upregulation of pro-apoptotic proteins Bax and Bad and downregulation of anti-apoptotic Bcl-2 and Bcl-xL | [ | ||
| Activity against breast cancer stem-like cells by reducing the expression of CD44, Oct4, Notch2, β-catenin and Sox2 proteins, associated with enhanced sensitivity of cells to the ionizing radiation and standard chemotherapeutic drugs (taxol, cisplatin and etoposide) | [ | ||
| The higher sensitization of colon cancer cells, HT-29 and HCT116, to 5-fluorouracil (5-FU) | [ | ||
| Eckol | Exhibition of radioprotective properties in vitro by ROS scavenging, and in vivo through the reduction of side effects caused by gamma ray-irradiation | [ | |
| Decreased expression of the stem-like glioma cells markers, CD133, Nestin and Musashi-1 | [ | ||
| Increased sensitivity of stem-like glioma cells to cytotoxic prodrug, temozolomide as well as to ionizing radiation via PI3K⁄Akt and Ras⁄Raf-1⁄ERK signalling pathways | |||
| Inhibition of the pancreatic cancer cell line (SW1990) growth | [ | ||
| Increase of cytotoxic T-lymphocytes required for annihilation of sarcoma (S180) xenograft in mouse model | [ | ||
| Phlorofucofuroeckol | Decreased HCT116, HT-29, LoVo and SW480 cells’ viabilities for 38%, 31%, 47% and 90%, respectively, at 100 μM | [ | |
| Induction of apoptosis and enhanced expression of activating transcription factor 3 (ATF3) | |||
| Suppression of migration and invasion of MCF-7 and MDA-MB-231 cells by downregulation of Nf-κB and Toll-like receptor 4 (TLR-4) alongside with reducing MMP-2 and -9 expression | [ | ||
| Dieckol | Suppression of migration and invasion of MCF-7 and MDA-MB-231 cells by downregulation of Nf-κB and Toll-like receptor 4 (TLR-4) alongside with reducing MMP-2 and -9 expression | [ | |
| Regulation of human fibrosarcoma cells’ (HT1080) invasion via downregulation of MMP-2 and -9 expression through Nf-κB signalling | [ | ||
| Inhibition of SK-Hep1 cells’ migration through downregulation of MMP-9 expression | [ | ||
| Decrease of B16F0 melanoma cells via downregulation of Ras-related C3 botulinum toxin substrate 1 (Rac1) and Wiskott–Aldrich syndrome protein family member 2 (WAVE2) | [ | ||
| Suppression of HT1080 cells migration via reduced expression and phosphorylation of focal adhesion kinase (FAK) | [ | ||
| Induction of apoptosis in Hep3B hepatocellular carinoma cell line through cytochrome | [ | ||
| Binding to MMP-2, MMP-9, MAPK, ERK and p38 via hydrogen bonds revealed by computational studies | [ | ||
| Suppression of ovarian cancer cells (A2780, SKOV3) growth by inducing caspase-dependent and regulating AKT and p38 signaling | [ | ||
| Reduced volume of SKOV3 tumor xenograft in mouse model | |||
| Reducing mobility of MCF-7 cells by increasing MMP inhibitors, TIMP-1 and -2, as well as degrading extracellular matrix | [ | ||
| Increase in Bax/Bcl-2 ratio indicating mitochondrial-mediated apoptosis in SK-BR-3 (breast cancer) and PANC-1 (pancreatic cancer) cells | [ | ||
| Protective and chemopreventing effects against hepatocellular carcinoma (HCC) in rats via upregulation of VEGF, MMP-2/9, PCNA and COX-2 | [ | ||
| Anti-migratory and apoptotic activity in A549 cells associated with inhibition of Pi3K/AKT/mTOR signalling pathways and activation of tumor-suppressor, E-cadherin | [ | ||
| Protection from gamma radiation and consequent damage, both in vitro and in vivo | [ | ||
| Diphlorethohydroxycarmalol | Activity against murine leukemia (P-388) and vincristine-resistant cells (IC50 = 10.5 and 8.0 µg/mL, respectively) | [ | |
| Induction of apoptosis in HL60 cells via upregulation of Bax, downregulation of Bcl-2 and increased expression of cleaved caspase-3 and cleaved PARP | [ | ||
| Photoprotective activity against UVB radiation and side effects, through absorption of radiation, inhibition of MMPs’ expression and scavenging of ROS | [ | ||
| Dioxinodehydroeckol | Induction of apoptosis in MCF-7 cells via downregulation of p65, IKK (IκB kinase) and NIK (NF-κB inducing kinase) | [ | |
| Downregulation of tyrosinase and tyrosinase-linked proteins (TRP-1 and TRP-2) as well as MITF (microphthalmia-associated transcription factor), involved in regulation of melanin formation in B16F10 mealnoma cells | [ | ||
| Protection against radiation-induced skin damage | [ | ||
| Fucodiphloroethol G | Activity against HeLa, A549, HT1080 and HT29 cancer cells (IC50 = 298.2, 226.5, 242.5 and 228.5 µM, respectively) | [ | |
| Suppression of MAPK and Akt signalling pathway necessary for expression of proteinases (MMP-2, MMP-9 and APN) involved in degradation of extracellular matrix | [ | ||
| Bis (2,3-dibromo-4,5-dihydroxybenzyl) ether (BDDE) | Bromophenol | Actvity against human myelogenous leukemia cells (K562) (IC50 = 13.9 µg/mL) | [ |
| Induction of mitochondrial pathway-related apoptosis via modulation of Bax, Bcl-2, caspases-3 and -9 in K562 cells | |||
| Topoisomerase I inhibitor by binding in the minor groove of DNA | |||
| Repression of angiogenesis through decrease in the VEGF and VEGFR expression in HUVEC cells associated with inhibition of subintestinal vessel formation in vivo on zebrafish embryos | [ | ||
| Bis (2,3-dibromo-4,5-dihydroxy-phenyl)-methane (BDDPM) | Anti-proliferative activity against HeLa, RKO, HCT116, Bel7402 and U87 human cancer cell lines (IC50 = 17.63, 11.37, 10.58, 8.7 and 23.69 µg/mL, respectively) | [ | |
| Mitochondrial-related apoptosis associated with the cleavages of caspases 3 and 9 and PARP | |||
| Inhibition of β1-integrin leading to suppression of Bel7402 cell migration and invasion | |||
| Inhibition of angiogenesis in HUVEC cells through inhibition of several receptor tyrosine kinases and reducing cell invasiveness by lowering the production of NO | [ | ||
| Antiproliferative activity against DLD-1 (IC50 = 18.3, 14.6, 13.5 and 12.4 µM) and HCT-116 cells (IC50 = 20.4, 14.1, 2.51 and 1.32 µM) | [ | ||
| Lanosol butanone | Antiproliferative activity against HL-60 cells (IC50 = 8.0 µM) | [ | |
| Bromophenol sulfate | Antiproliferative activity against A2780 cancer cells (IC50 = 9.4 µM) | [ | |
| Avrainvilleal | Moderate activity against HeLa cancer cells (IC50 = 9.64 ± 1.7 µM) | [ | |
| Penimethavone A | Flavonoid | Antiproliferative activity against HeLa and RD cancer cells (IC50 = 8.41 and 8.18 µM) | [ |
| Isorhamnetin-3- | Inhibition of MMP-2 and MMP-9 in Ht1080 cells, associated with increase in TIMP-1 protein | [ | |
| Quercetin-3- | |||
| Antiproliferative activity against HCT116 cancer cells (IC50 = 24.3 µM) | [ | ||
| Myricetin 3-galactoside | Suppression of MMP-2 and MMP-9 expression while simultaneously elevating TIMP-1 and TIMP-2 at the mRNA and protein levels in HT1080 cell line | [ | |
| Quercetin 3- | |||
| Reduced the levels of phosphorylated ERK and p-38 in HT1080 cell lines | |||
| Alternariol | Coumarins | Antiproliferative activity against KB and KBv200 cancer cells (IC50 = 3.17 and 4.82 µM) | [ |
| Anticancer properties against leukemia cell lines (L1210 and CCRF-CEM) | [ | ||
| Alternariol methyl ether | Antiproliferative activity against KB and KBv200 cancer cells (IC50 = 3.12 and 4.94 µM) | [ | |
| Antiproliferative properties against leukemia cell lines (Colon-38 and H-125) | [ | ||
| Lamellarin D | Antiproliferative activity against LNCaP, DU-145 and K562 cancer cells in the nanomolar range | [ | |
| Antiproliferative activity against CEM and CEM/C2 lines (14 and 969 nM) | [ | ||
| Topoisomerase I inhibitor due to intercalation at the DNA–topoisomerase I complex | |||
| Induction of apoptosis of P388 and P388CPT5 (topoisomerase I—mutated subclone) cells via increasing the levels of Bax and decreasing the expression of Bcl-2 and cIAP2 along with caspase-3/-9 activation | [ | ||
| Lamellarin M | Antiproliferative activity against P388, Schabel, AUXB1, CCHRC5, A549, HT29 and MEL28 cancer cells (IC50 = 0.15, 0.17, 0.07, 0.17, 0.06, 0.56 and 0.54 µM) | [ | |
| Lamellarin K | Antiproliferative activity against P388, Schabel, AUXB1, CCHRC5, A549, HT29 and MEL28 cancer cells (IC50 = 0.19, 0.017, 0.19, 0.75, 0.18, 0.38 and 0.40 µM) | ||
| Aspergiolide A | Antiproliferative activity against A-549, HL-60, BEL-7402 and P388 cancer cells (IC50 = 0.13, 0.28, 7.5 and 35 µM) | [ | |
| Activity against 11 cancer cells with micromolar IC50 values (2.37–7.07 μM) | [ | ||
| Induction of caspase-mediated apoptosis of BEL-7402 cancer cells via modulation of Bax and Bcl-2 expression | |||
| Inhibition of DNA topoisomerase II | |||
| Suppressing the increase of H22 and BEL-7402 cancer xenografts in mice without major effects on body weight | |||
| Aspergiolide B | Antiproliferative activity against A-549 and HL-60 cancer cells (IC50 = 0.24 and 0.51 µM) | [ | |
| Potential EGFR-TK inhibitor displaying low binding free energy in active site containing MET-766, THR-790 and THR-854 amino acid residues | [ | ||
| Epitaondiol ( | Terpenophenolics | The highest activity of almost 100% inhibition of cell proliferation was observed against human neuroblastoma cells (SH-SY5Y) | [ |
| Flabellinol | Antiproliferative activity against mouse neuroblastoma cell line (Neuro-2a) and NCI-H460 cells (IC50 = 9 µM) | [ | |
| Laurebiphenyl | Antiproliferative activity against BGC-823, HeLa, A549, HCT-8 and Bel7402 cancer cells (IC50 = 1.22, 1.61, 1.68, 1.77 and 1.91 µM) | [ | |
| 7-Hydroxylaurene | Antiproliferative activity against MCF-7, PC3, A431, HeLa and K562, as well as CHO cancer cells (IC50 = 15.8, 18.1, 23.9, 40.5, 64.2 and 78.2 µM) | [ | |
| (+)-curcuphenol | Antiproliferative activity against P388 cancer cells (IC50 = 7 µg/mL) | [ | |
| Antiproliferative activity against p53+/+, p53−/−, p21+/+ and p21−/− cancer cells (IC50 = 27, 33, 33 and 35 µg/mL) | [ | ||
| Inhibition of CaCo-2 colon proliferation and DNA synthesis associated with induction of apoptosis via caspase-3 activation | [ | ||
| Sargaquinoic acid ( | Antiproliferative activity against P388 cancer cells (IC50 = 17 and 14 µM) | [ | |
| Plastoquinones | Antiproliferative activity against murine colon 26-L5 adenocarcinoma cell line (IC50 = 1.51 and 1.69 μg/mL) | [ | |
| Moromycin B ( | Quinones and hydroquinones | Inhibition of proliferation of breast cancer cells (MCF-7, MDA-MB-231 and BT-474) in sub-micromolar range (0.16–0.67 μM) | [ |
| Saquayamycin B ( | Suppression of MDA-MB-231 cells invasion and migration at concentrations of 25 and 50 nM for 12 h | ||
| Buanmycin | Antiproliferative activity against A549, HCT116, SNU638, SK-HEP1 and MDA-MB-231 cancer cells (IC50 = 1.7, 0.9, 0.8, 1.9 and 1.2 μM) | [ | |
| Komodoquinone A | Morphological changes and neuritogenic activity against neuroblastoma cell line (Neuro 2A) | [ | |
| Induction of Neuro 2A cell cycle arrest at G1 phase | |||
| Fradimycin B | Antiproliferative activity against HCT-15, SW620 and C6 cancer cells (IC50 = 0.13, 4.33 and 0.47 μM) | [ | |
| Induction of cell cycle arrest at G0/G1 phase associated with an increase of apoptotic and necrotic cells | |||
| Makaluvamine J | Antiproliferative activity against PANC-1 (IC50 = 0.054 μM) and OVCAR-5 cancer cells (IC50 = 120 nM) | [ | |
| Makaluvamine F | Antiproliferative activity against HCT-116 (IC50 = 0.17 μM) | [ | |
| Role in hypoxia conditions via inhibition of HIF-1α and its downstream target, VEGF | [ | ||
| Mayamycin | Antiproliferative activity against eight cancer cell lines: HepG2, HT-29, GXF251L, LXF529L, MAXF401NL, MEXF462NL, PAXF1657L and RXF486L (IC50 = 0.2, 0.3, 0.2, 0.16, 0.29, 0.13, 0.15 and 0.33 μM) | [ | |
| Antiproliferative activity against U251, U87-MG, SHG-44 and C6 glioma cell lines (IC50 = 0.7, 1.4, 3.9 and 0.5 μM) | [ | ||
| Induction of apoptosis in U251 cells | |||
| Monacyclinone F | Antiproliferative activity against rhabdomycosarcoma cancer cells (SJCRH30) (EC50 = 0.73 μM) | [ | |
| Galvaquinone B | Antiproliferative activity against Calu-3 and H2887 cancer cells (SJCRH30) (IC50 = 5.0 and 12.2 μM) | [ | |
| Lupinacidin A | Antiproliferative activity against Calu-3 and H2887 cancer cells (SJCRH30) (IC50 = 8.8 and 3.1 μM) | ||
| Hierrdin B | Antiproliferative activity against HT-29 cancer cells (IC50 = 100 μM) | [ | |
| Targeting mitochondrial activity by increasing mRNA expression of VDAC1 accompanied with inhibition of cell cycle progression | [ | ||
| Norhierridin B | Antiproliferative activity against MDA-MB-231, SKBR3, MDA-MB-468, A375, Huh-7 and HCT116 cancer cells (IC50 = 0.61, 0.77, 0.68, 2.0, 0.61 and 3.2 μM) | [ | |
| Diorcinol L | Miscellaneous | Antiproliferative activity against Huh-7, DU145, HeLa and HL60 cancer cells (IC50 = 5.7, 9.1, 7.1 and 9.6 µM) | [ |
| Sulochrin | Antiproliferative activity against L5178Y cancer cells (IC50 = 5.1 µM) | [ | |
| Inhibition of MDA-MB-231 cell migration | |||
| Inhibition of CDK-2, TOP-2 and MMP-13 proteins | |||
| Penicitrinine A | Antiproliferative activity against A-375 cancer cells (IC50 = 30.88, 12.78 and 7.06 µM, after treatment for 24 h, 48 h and 72 h, respectively) | [ | |
| Induction of apoptosis of A-375 cells by modulation of Bcl-2 and Bax expression | |||
| Suppression of A-375 cell migration by downregulating MMP-9 and upregulating TIMP-1 levels | |||
| Psammaplin A | Inhibition of aminopeptidase N (APN), mycothiol-S-conjugate amidase (MCA), topoisomerase II, farnesyl protein transferase, histone deacetylase (HDAC) and leucine aminopeptidase, involved in angiogenesis, DNA replication, apoptosis, proliferation and invasion | [ | |
| Secalonic acid D | Antiproliferative activity against PANC-1, S1, S1-MI-80, H460, H460/MX20, MCF-7 and MCF-7/ADR cancer cells (IC50 = 0.6, 6.8, 6.4, 5.3, 4.9, 5.1 and 4.9 µM) | [ | |
| Induction of cell death through c-Jun/Src/STAT3 signalling by upregulation of c-Jun expression | [ | ||
| Inhibition of eNOS and ERK phosphorylation together with MMP degradation via Akt/mTOR/p70S6K pathway | [ | ||
| Secalonic acid F | Antiproliferative activity against HL-60 cancer cells (IC50 = 4.1 µg/mL) | [ | |
| Induction of apoptosis via caspase-3 activation and modulation of RhoGDI2 protein | |||
| Antiproliferative activity against HepG2 cancer cells (IC50 = 45.4, 8.7 and 7.7 µM, after treatment for 24 h, 48 h and 72 h, respectively) | |||
| Cell cycle arrest at the G1 phase and apoptosis induction activating caspases-3 and -9 | |||
| Suppression of HepG2 and Hep3B cells invasion via downregulation of MARCH1 | [ | ||
| Toxicity towards leukemia and multiple myeloma cells mediated through apoptosis and necrosis as well as tubulin disassembly | [ |